11.10.2024  22:00:00 Изменение +0.0500 Объем сделки Бид0:00:00 Предложение0:00:00 Рыночная капитализация Дивидендная доходность Коэффициент Цена/Доход
11.3800USD +0.44% 4.22 млн
Оборот: 31.96 млн
11.3200Величина цены спроса: 300 11.4200Величина цены предложения: 200 13.58 млрдUSD 4.22% 227.60

Описание деятельности

Viatris Inc. is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway™. Formed in November 2020 through the combination of Mylan and Pfizer's Upjohn business, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products. With a global workforce of approximately 45,000, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India.
 

Правление & Наблюдательный совет

Исполнительный директор
Scott A. Smith
Правление
Sanjeev Narula, Rajiv Malik, Robert J. Coury
Наблюдательный совет
Robert J. Coury, W. Don Cornwell, JoEllen Lyons Dillon, Elisha W. Finney, Leo Groothuis, Melina Higgins, James Kilts, Harry A. Korman, Rajiv Malik, Richard A. Mark, Mark W. Parrish, Scott A. Smith, Pauline van der Meer Mohr
 

Данные компании

Имя: Viatris Inc.
Адрес: 1000 Mylan Boulevard, Canonsburg,Pennsylvania, 15317, USA
Телефон: +1-724-514-1800
Факс: -
E-mail: -
Интернет: https://www.viatris.com/en
Индустрия: Healthcare
Сектор: Pharmaceutical Industry
Подсектор: Pharmaceuticals
Конец финансового года: 31.12
Акции в свободном обращении: -
Дата IPO: 16.11.2020

Связи с инвесторами

Имя: Bill Szablewski
IR телефон: +1-412-707-2866
IR-факс: -
IR e-mail: InvestorRelations@viatris.com

Основные акционеры

Другие
 
55.73%
Vanguard Group Inc
 
11.94%
BlackRock Inc.
 
7.75%
Davis Selected Advisers, LP
 
5.26%
State Street Corporation
 
5.20%
Price T Rowe Associates Inc Md
 
4.15%
Invesco Ltd.
 
2.53%
Geode Capital Management, LLC
 
2.30%
Pacer Advisors Inc
 
1.75%
Другие
 
3.39%